In the context of the PD-1/PD-L1 axis, recent studies have demonstrated that breast cancer patients with low levels of PD-1+ tumor-infiltrating lymphocytes (TILs) and high expression of PD-L1 within tumors showed the worst survival rate. This evidence concerns the gene PDCD1 and breast carcinoma.